Multiple Sclerosis Therapy: Disease-modifying Treatment I
Sunday April 23, 2017 1:00 pm to 3:00 pm
MS and CNS Inflammatory Disease
Bruce Cree MD, PhD, MCR, FAAN
Disease-modifying treatments in MS are one of the most rapidly evolving areas of therapeutic intervention in neurology. As new treatments become available, the options for patients, and their prescribing physicians, increases. Many of the newer therapies have complex risk: benefit profiles and require specialized expertise for safe and effective administration. Faculty will focus on therapeutic strategies and risk mitigation of currently available disease-modifying therapies, discuss proper use of these drugs and risk assessment, and use specific examples to cover the most frequent issues arising from MS treatment strategies.
This program complements C54: Multiple Sclerosis Therapy: Disease-modifying Treatment II and C116: Multiple Sclerosis Therapy: Symptom Management, but covers independent topics.
Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents.
Medical Knowledge, Patient Care
Program Speakers - Tentative
1:00 PM - 1:55 PM
Immunomodulation Versus Immunosuppression: Mechanism of Action of Multiple Sclerosis Drugs
Scott S. Zamvil MD, PhD, FAAN
1:55 PM - 2:00 PM
Questions and Answers
2:00 PM - 2:55 PM
Considering DMT: Escalation, Induction, Sequencing and Exit Strategy
Timothy W. West MD
2:55 PM - 3:00 PM
Questions and Answers
Timothy W. West, MD
Dr. West has received personal compensation for activities with Biogen, EMD Serono, Teva Neuroscience, Genzyme, Novartis, and Genentech.
Scott S. Zamvil, MD, PhD, FAAN
Dr. Zamvil has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with I have attended advisory board meetings for Novartis and Genzyme. I have given three talks for Teva.. Dr. Zamvil has received personal compensation in an editorial capacity for AAN, I am Deputy Editor of Neurology, Neuroimmunology and Neuroinflammation. Dr. Zamvil has received research support from I have grant support from Biogen, Teva and Celgene. .
Ready to register for the 2018 AAN Annual Meeting?